Ocular Therapeutix Appoints New CMO, Director
Ticker: OCUL · Form: 8-K · Filed: Oct 9, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Oct 9, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
Related Tickers: OCUL
TL;DR
OCULAR THERAPEUTIX just hired a new CMO and added a director to the board.
AI Summary
Ocular Therapeutix, Inc. announced on October 4, 2024, the appointment of Dr. Jonathan T. Miller as Chief Medical Officer and the election of Ms. Amy T. Peterson to its Board of Directors. The company also reported on compensatory arrangements for its named executive officers. These changes are effective as of October 4, 2024.
Why It Matters
The appointment of a new Chief Medical Officer and a new board member can signal strategic shifts in the company's medical and governance direction, potentially impacting future research and development or business strategy.
Risk Assessment
Risk Level: low — This filing primarily concerns personnel changes and does not involve significant financial transactions or operational disruptions.
Key Players & Entities
- Ocular Therapeutix, Inc. (company) — Reporting company
- Dr. Jonathan T. Miller (person) — Appointed Chief Medical Officer
- Ms. Amy T. Peterson (person) — Elected to Board of Directors
- October 4, 2024 (date) — Effective date of appointments and elections
FAQ
Who has been appointed as the new Chief Medical Officer of Ocular Therapeutix, Inc.?
Dr. Jonathan T. Miller has been appointed as the new Chief Medical Officer.
When were the appointments and elections effective?
The appointments and elections were effective as of October 4, 2024.
Who was elected to the Board of Directors?
Ms. Amy T. Peterson was elected to the Board of Directors.
What other information is covered in this 8-K filing?
The filing also covers compensatory arrangements of certain officers.
What is the principal executive office address for Ocular Therapeutix, Inc.?
The principal executive offices are located at 15 Crosby Drive, Bedford, MA 01730.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 12.5 · Accepted 2024-10-09 16:20:57
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm2425873d1_8k.htm (8-K) — 24KB
- tm2425873d1_ex99-1.htm (EX-99.1) — 3KB
- 0001104659-24-107348.txt ( ) — 194KB
- ocul-20241004.xsd (EX-101.SCH) — 3KB
- ocul-20241004_lab.xml (EX-101.LAB) — 33KB
- ocul-20241004_pre.xml (EX-101.PRE) — 22KB
- tm2425873d1_8k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits: 99.1 Amendment No. 4 to 2019 Inducement Stock Incentive Plan 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: October 9, 2024 By: /s/ Donald Notman Donald Notman Chief Operating Officer and Chief Financial Officer